| 张晓娟,刘松涛,韩荦杰,贺英,许珊珊,刘海港,张莉,张顺.曲唑酮联合氟伏沙明治疗抑郁症伴发失眠的疗效及对多导睡眠图、血清肽类神经递质、IL-1β水平的影响.[J].中南医学科学杂志.,2024,(5):760-763, 818. |
| 曲唑酮联合氟伏沙明治疗抑郁症伴发失眠的疗效及对多导睡眠图、血清肽类神经递质、IL-1β水平的影响 |
| Efficacy of trazodone combined with fluvoxamine on the treatment of depression with insomnia and the effects on polysomnography and serum levels of peptide neurotransmitters and IL-1β |
| 投稿时间：2023-10-23 修订日期：2024-09-03 |
| DOI：10.15972/j.cnki.43-1509/r.2024.05.016 |
| 中文关键词: 抑郁症 失眠 曲唑酮 氟伏沙明 多导睡眠图 肽类神经递质 IL-1β |
| 英文关键词:depression insomnia trazodone fluvoxamine polysomnography peptide neurotransmitters IL-1β |
| 基金项目:河北省医学科学研究重点课题计划(20210818) |
| 作者 | 单位 | E-mail | | 张晓娟 | 开滦医疗健康产业集团开滦精神卫生中心睡眠病区,河北唐山 063000 | e-mail为zxju256@163.com,e-mail为myzhsh@126.com | | 刘松涛 | 开滦医疗健康产业集团开滦精神卫生中心睡眠病区,河北唐山 063000 | | | 韩荦杰 | 开滦医疗健康产业集团开滦精神卫生中心睡眠病区,河北唐山 063000 | | | 贺英 | 开滦医疗健康产业集团开滦精神卫生中心睡眠病区,河北唐山 063000 | | | 许珊珊 | 开滦医疗健康产业集团开滦精神卫生中心睡眠病区,河北唐山 063000 | | | 刘海港 | 开滦医疗健康产业集团开滦精神卫生中心睡眠病区,河北唐山 063000 | | | 张莉 | 开滦医疗健康产业集团开滦精神卫生中心睡眠病区,河北唐山 063000 | | | 张顺 | 开滦医疗健康产业集团开滦精神卫生中心睡眠病区,河北唐山 063000 | e-mail为zxju256@163.com,e-mail为myzhsh@126.com |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的观察曲唑酮联合氟伏沙明治疗抑郁症伴发失眠的疗效及对多导睡眠图、血清肽类神经递质、白细胞介素(IL)-1β水平的影响。 方法选取本院抑郁症伴发失眠症状患者360例,根据治疗方法不同均分为对照组(马来酸氟伏沙明治疗)和观察组(盐酸曲唑酮联合马来酸氟伏沙明治疗)。比较两组治疗前后汉密尔顿抑郁量表17项(HAMD-17)、匹兹堡睡眠质量指数(PSQI)、健康调查量表36项(SF-36)评分以及多导睡眠图参数、血清神经肽Y(NPY)、P物质(SP)、IL-1β水平。比较两组临床疗效及不良反应发生情况。 结果与治疗前比较,治疗后两组HAMD-17、PSQI总分、SP、IL-1β水平降低(P＜0.05),SF-36总分、NPY水平升高(P＜0.05)；总睡眠时间、快速眼动-睡眠时间、慢波睡眠时间延长(P＜0.05),觉醒次数减少(P＜0.05),睡眠效率提高(P＜0.05),睡眠潜伏期、觉醒时间缩短(P＜0.05),且以观察组改善更显著(P＜0.05)。观察组总有效率高于对照组(P＜0.05)。两组不良反应发生率差异无显著性(P＞0.05)。 结论曲唑酮联合氟伏沙明对抑郁症伴发失眠症状患者的抑郁症状、睡眠进程及结构均有明显改善效果,可有效提高总体疗效,并能良性调节血清相关肽类神经递质及IL-1β水平,且患者耐受性较好。 |
| 英文摘要: |
| AimTo observe the clinical efficacy of trazodone combined with fluvoxamine on the treatment of depression with insomnia and the effects on polysomnogram, serum peptide neurotransmitter, interleukin(IL)-1β levels. Methods360 patients with depression accompanied by insomnia were selected and divided into control group (fluvoxamine maleate treatment) and observation group (trazodone hydrochloride combined with fluvoxamine maleate treatment) according to different treatment methods. 17 items of Hamilton depression scale (HAMD-17), Pittsburgh sleep quality index (PSQI), 36-item short form health survey (SF-36) scores, polysomnography parameters, serum neuropeptide Y (NPY), substance P (SP) and IL-1β levels were compared between the two groups before and after treatment. The clinical efficacy and adverse reactions were compared between the two groups. ResultsCompared with parameters before treatment, the total score of HAMD-17, PSQI, SP, IL-1β levels were decreased after treatment (P＜0.05), while the total score of SF-36 and serum NPY levels were increased (P＜0.05). Total sleep time, rapid eye movement-sleep time and slow-wave sleep time were significantly extended (P＜0.05), wake times was decreased (P＜0.05), sleep efficiency was increased (P＜0.05), and sleep latency and wake time were shortened (P＜0.05). The improvement was more significant in the observation group (P＜0.05). The total effective rate of observation group was higher than that of control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionTrazodone combined with fluvoxamine can significantly improve the depressive symptoms, sleep process and structure of patients with depression and insomnia symptoms, effectively improve the overall treatment effect, and can regulate the levels of serum related peptide neurotransmitters and IL-1β in a benign manner, with good patient tolerance. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|